“The scheme enabled Gilead and its co-conspirators to unlawfully extend patent protection for their drugs, impair entry by generic competitors, and charge exorbitant, supra-competitive prices for the drugs that people living with HIV need to survive,” the lawsuit says.
Gilead called the claims meritless in a statement, saying the suit “distorts and misstates Gilead’s history and its collaborations with these ...